BeiGene Receives Positive CHMP Opinion For BRUKINSA (zanubrutinib) In Relapsed Or Refractory Follicular Lymphoma
Portfolio Pulse from Benzinga Newsdesk
BeiGene's BRUKINSA (zanubrutinib) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in relapsed or refractory follicular lymphoma. The CHMP recommends approval for BRUKINSA plus obinutuzumab as a treatment for adult patients who have received at least two prior lines of therapy. If approved, BRUKINSA will be the first and only BTK inhibitor approved for follicular lymphoma.
October 13, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene's BRUKINSA has received a positive CHMP opinion, which could lead to its approval as a treatment for follicular lymphoma. This could potentially increase BeiGene's market share and revenues.
The positive opinion from CHMP is a significant step towards the approval of BRUKINSA for follicular lymphoma. If approved, it will be the first and only BTK inhibitor for this condition, which could potentially increase BeiGene's market share and revenues. This is highly relevant and important for BeiGene and its investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100